To date, the U.S. Food and Drug Administration has approved several PSMA-targeted PET imaging agents for the imaging of PSMA-positive lesions in patients with newly diagnosed or recurrent PC at risk for metastases (11–13). This evidence concerns the gene FOLH1 and pachyonychia congenita.